The global SGLT-2 Inhibitors Market is poised for substantial growth in 2021 and beyond. This growth is primarily driven by the increasing prevalence of diabetes mellitus, a chronic condition characterized by elevated blood sugar levels. The World Health Organization (WHO) reports a significant rise in diabetes cases, with the number of affected individuals soaring from 108 million in 1980 to a staggering 422 million in 2014. This alarming trend is more pronounced in low- and middle-income countries, where diabetes rates are escalating at an even faster pace. Tragically, diabetes-related premature mortality increased by 5% between 2000 and 2016, with an estimated 1.5 million global deaths attributed directly to the disease, making it the ninth leading cause of death worldwide.
Type 2 diabetes, also known as non-insulin-dependent or adult-onset diabetes, is the most prevalent form of the disease, affecting over 95% of diabetic patients. It is primarily linked to factors such as being overweight and leading a sedentary lifestyle. The modern sedentary way of life, characterized by minimal physical activity, has contributed significantly to the expansion of the SGLT-2 inhibitors market over the forecast period.
Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/5343
Drivers for Market Growth:
The global SGLT2 market is expected to experience robust growth due to the increasing burden and severity of diabetes mellitus worldwide. According to the National Institute of Health, approximately 462 million people, or 6.28% of the world's population, had type 2 diabetes in 2017. This translates to a prevalence rate of 6,059 cases per 100,000 people, affecting individuals of all age groups. Diabetes alone is responsible for nearly 1 million deaths annually, ranking it as the ninth leading cause of death globally.
The surge in diabetes prevalence can be attributed to significant lifestyle changes, dietary habits, and the consumption of unhealthy junk food. Moreover, increased alcohol and tobacco use have exacerbated this global health issue. The rising rates of obesity, closely associated with diabetes, have further driven the incidence of the disease, thereby positively impacting the market for SGLT2 inhibitors.
Geographic Market Scenario:
- Largest Market Share (North America): North America, particularly the United States, is expected to dominate the market with the highest revenue share. The prevalence of diabetes is rising rapidly in the U.S., with over 34.2 million Americans, or approximately 1 in 10, living with the condition. Type 2 diabetes accounts for 90–95% of these cases. Factors contributing to market growth in North America include robust research and development efforts, technological advancements, the presence of major pharmaceutical companies, increased acceptance of innovative treatments, improved healthcare infrastructure, and heightened public awareness. Lifestyle factors, including obesity, dietary choices, sedentary behavior, and substance use, are also driving the growth of the market.
- Fastest Growing Region (Asia Pacific): The Asia Pacific region is expected to witness the fastest growth in the SGLT-2 inhibitors market. This growth can be attributed to a large patient pool, a surge in diabetes prevalence, rising disposable incomes, increased public awareness, improved healthcare infrastructure, and heightened research and development activities. China is a key player in this region, with South Korea, Australia, and India also contributing to the rapid market expansion.
Key Market Trends and Innovation:
SGLT-2 inhibitors, with their unique mechanism of reducing renal tubular glucose reabsorption and lowering blood glucose levels without insulin release, are at the forefront of the diabetic market. Leading the SGLT2 market is Jardiance, developed by Boehringer Ingelheim. This once-daily oral medication is favored by individuals with type 2 diabetes due to its lower cardiovascular risk and more effective blood sugar level management compared to other SGLT2 drugs.
Organic and Inorganic Strategies:
Key players in the SGLT2 inhibitors market are adopting both organic and inorganic strategies to advance their products and expand their market reach. For instance:
- In February 2022, Boehringer Ingelheim received FDA approval for additional use of Jardiance (empagliflozin) to lower the risk of hospitalization and death in patients with heart failure and a poor ejection fraction, as well as in people with type 2 diabetes and pre-existing cardiovascular disease.
- In April 2021, AstraZeneca received FDA authorization to market Farxiga (dapagliflozin) for additional use, specifically for the prevention of cardiovascular death, kidney failure, kidney function loss, and heart failure hospitalization in individuals with chronic kidney disease at risk of disease progression.
- In January 2020, the FDA approved Trijardy XR, developed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. This once-daily pill combines three well-known medications, including Jardiance (empagliflozin), Tradjenta (linagliptin), and metformin hydrochloride extended-release, to reduce blood sugar levels in individuals with type 2 diabetes, in conjunction with diet and exercise.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/5343
Key Market Players:
Prominent players in the SGLT2 inhibitors market include:
- AstraZeneca
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Glenmark Pharmaceuticals
- Mankind Pharma Ltd.
- Torrent Pharmaceuticals Ltd.
- Lupin Pharmaceuticals, Inc.
- Janssen Pharmaceuticals
- USV Ltd.
- Abbott
- Sun Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- GSK Plc.
What Our Report Provides and Why Our Offering Is Superior:
Our comprehensive report offers historical data, forecasts, and revenue growth at global, regional, and country levels. It provides in-depth analysis of industry trends, consumption patterns, and industry strategies for each region, major country, and segment from 2019 to 2030. The report covers a wide range of topics, including industry drivers, restraints, opportunities, threats, market strategies, segment revenue, and revenue share contributions from each regional and country market. Additionally, it offers industry analysis, a competitive landscape, company financials, and impact analysis.
Product Type Outlook:
The market includes various product types, such as solid dosage forms like tablets and capsules.
Route of Administration Outlook:
SGLT2 inhibitors can be administered orally or through other routes.
Drug Class Outlook:
The market features different drug classes, including canagliflozin, dapagliflozin, and empagliflozin.
Distribution Channel Outlook:
These inhibitors can be obtained through various distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
End-User Outlook:
End-users of SGLT2 inhibitors include hospitals, homecare settings, and clinics.
Regional Outlook:
The report covers regional markets, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, providing insights into each region's market dynamics and growth prospects.
Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/5343
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports:
Acute Coronary Syndrome (ACS) Treatment Market
Palmoplantar Pustulosis Treatment Market
Lumbar Spondylolisthesis Market
Fungal Pneumonia Treatment Market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
